key: cord-0928956-lrnj3tdw
authors: Marinaki, Smaragdi; Adamopoulos, Stamatis; Degiannis, Dimitrios; Roussos, Sotirios; Pavlopoulou, Ioanna D.; Hatzakis, Angelos; Boletis, Ioannis N.
title: Immunogenicity of SARS‐CoV‐2 BNT162b2 vaccine in solid organ transplant recipients
date: 2021-05-07
journal: Am J Transplant
DOI: 10.1111/ajt.16607
sha: 393537cf197d7f34b4b5385329a1879698a8179e
doc_id: 928956
cord_uid: lrnj3tdw

Solid organ transplant (SOT) recipients represent a high-risk group for all SARS-COV-2 infection-related adverse outcomes. Therefore, most European countries have established prioritization of SOTrecipients in their vaccination programs. Suboptimal vaccine efficacy to the SARS-COV-2 vaccines is anticipated; however, they have been excluded from vaccination trials. Overall response rates to other vaccines as influenza have demonstrated high, though acceptable, variability.

To the Editor:

Solid organ transplant (SOT) recipients represent a high-risk group for all SARS-CoV-2 infection-related adverse outcomes. 1 immunosuppression was the only factor that negatively influenced immune response: 33% in those receiving MPA versus 79% in those who did not (adjusted incidence ratio IRR 0.42, p = .027) ( Table 1 ).

The study was underpowered for the assessment of immunogenicity by transplantation type. When SOT recipients were compared to HCW, antibody response rates (58.8% vs. 100%, p < .001), me- 

Factors associated with COVID-19-related death using Open SAFELY

Influenza vaccination in the organ transplant recipient: review and summary recommendations

Anti-Spike protein assays to determine post vaccination antibody levels: a head to head comparison of five quantitative assays

Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

Email: smaragdimarinaki@yahoo.com

https://orcid.org/0000-0002-5920-3086